Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Norifumi Harimoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8085-2857; OpenAlex author ID A5010990293, A5045950085. Sources: OpenAlex.

Their work

Papers
13 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 4 papers · 2021: none · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper

Papers 13

  1. Combined effect of frailty and sarcopenia on postoperative complications in older adults undergoing curative surgery for hepato-biliary-pancreatic cancer. Co-author DOI 10.1002/ags3.12897↗
  2. Potential of Mac-2-binding protein glycan isomer as a new therapeutic target in pancreatic cancer. Co-author DOI 10.1111/cas.16087↗
  3. Usefulness of serum creatinine and cystatin C ratio as a screening tool for predicting prognosis in patients with pancreatic cancer. Co-author DOI 10.1002/ags3.12671↗
  4. High RRN3 expression is associated with malignant characteristics and poor prognosis in pancreatic cancer. Co-author DOI 10.1007/s10147-023-02342-w↗
  5. D-Dimer Could Be a Surrogate Postoperative Prognostic Marker of Resectable Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000001537↗
  6. Long-term survival of two patients with pancreatic cancer after resection of liver and lung oligometastases: a case report. First author DOI 10.1186/s40792-020-01029-y↗
  7. High Co-expression of Large Tenascin C Splice Variants in Stromal Tissue and Annexin A2 in Cancer Cell Membranes is Associated with Poor Prognosis in Pancreati… First author DOI 10.1245/s10434-019-07708-x↗
  8. ASO Author Reflections: Clinical Significance of Large Tenascin C Splice Variants and Annexin A2 for Pancreatic Cancer. First author DOI 10.1245/s10434-019-08009-z↗
  9. Conophylline suppresses pancreatic cancer desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts. Co-author DOI 10.1111/cas.13847↗
  10. High STMN1 Expression Is Associated with Tumor Differentiation and Metastasis in Clinical Patients with Pancreatic Cancer. Co-author DOI 10.21873/anticanres.12307↗
  11. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer. Co-author DOI 10.1002/cam4.1087↗
  12. Surgical Results of Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: a Multi-institutional Retrospective Study of 174 patients. Co-author PMID 27127150↗
  13. Recurrence 11 years after complete response to gemcitabine, 5-Fluorouracil, and Cisplatin chemotherapy followed by radiotherapy in a patient with advanced panc… Co-author PMID 25964569↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ken Shirabe · 10 shared papers, 2015–2024 · strength 1.19
  2. Kei Hagiwara · 9 shared papers, 2018–2024 · strength 1.14
  3. Akira Watanabe · 8 shared papers, 2018–2024 · strength 0.95
  4. Kenichiro Araki · 8 shared papers, 2018–2024 · strength 0.95
  5. Norihiro Ishii · 7 shared papers, 2018–2024 · strength 0.84
  6. Mariko Tsukagoshi · 7 shared papers, 2018–2024 · strength 0.84
  7. Takahiro Yamanaka · 6 shared papers, 2018–2024 · strength 0.66
  8. Takehiko Yokobori · 5 shared papers, 2018–2024 · strength 0.56
  9. Takamichi Igarashi · 4 shared papers, 2018–2020 · strength 0.34
  10. Keishi Sugimachi · 2 shared papers, 2016–2025 · strength 0.29
  11. Atsushi Masamune · 2 shared papers, 2019–2024 · strength 0.26
  12. Tomonari Shimagaki · 1 shared paper, 2025 · strength 0.25
  13. Masaru Morita · 1 shared paper, 2025 · strength 0.25
  14. Kiyoaki Ito · 1 shared paper, 2024 · strength 0.18
  15. Tomoharu Yoshizumi · 3 shared papers, 2015–2017 · strength 0.16
  16. Shinji Itoh · 3 shared papers, 2015–2017 · strength 0.16
  17. Yoshihiko Maehara · 3 shared papers, 2015–2017 · strength 0.16
  18. Chingunjav Batbayar · 1 shared paper, 2023 · strength 0.15
  19. Hiroyuki Kuwano · 2 shared papers, 2018–2019 · strength 0.14
  20. Toru Ikegami · 2 shared papers, 2016–2017 · strength 0.11
  21. Yuji Soejima · 2 shared papers, 2016–2017 · strength 0.11
  22. Yo Ichi Yamashita · 2 shared papers, 2015–2016 · strength 0.09
  23. Kazunobu Suzuki · 1 shared paper, 2018 · strength 0.07
  24. Yoshinao Oda · 1 shared paper, 2017 · strength 0.06
  25. Daisuke Imai · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.